SILO
Silo Pharma, Inc.
Key Financials
Revenue
$72102
0.0%
Net Income
$-4227698
↑ 3.8%
Gross Profit
$27807
↓ 58.0%
Total Liabilities
$1.3M
↓ 45.3%
Total Assets
$7.6M
↑ 2.6%
Shareholders' Equity
$6.3M
↑ 25.3%
EPS (Diluted)
$-0.50
↑ 58.0%
Operating Income
$-4280662
↑ 9.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/2/2026 | View on SEC |
| 8-K | 8/19/2026 | View on SEC |
| 8-K | 8/17/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| EFFECT | 8/6/2026 | View on SEC |
| 424B3 | 8/6/2026 | View on SEC |
| S-8 | 7/31/2026 | View on SEC |
| S-3 | 7/24/2026 | View on SEC |
| D | 7/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SILO |
| Company Name | Silo Pharma, Inc. |
| CIK | 1514183 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | (718) 400-9031 |